Fred Zeidman Buys 12,500 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Fred Zeidman purchased 12,500 shares of Bluejay Diagnostics stock in a transaction on Saturday, March 14th. The stock was bought at an average cost of $2.00 per share, with a total value of $25,000.00. Following the transaction, the director directly owned 12,500 shares of the company’s stock, valued at approximately $25,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Bluejay Diagnostics Price Performance

Shares of NASDAQ:BJDX opened at $1.71 on Wednesday. Bluejay Diagnostics, Inc. has a fifty-two week low of $1.62 and a fifty-two week high of $16.68. The business has a 50-day moving average of $1.89 and a two-hundred day moving average of $3.14. The stock has a market capitalization of $1.76 million, a P/E ratio of -0.15 and a beta of 0.72.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.